Fig. 1 · Structure

Documents & Downloads

PCI-34051

Cat. No. A11152 CAS 950762-95-5

HDAC inhibitor

PCI-34051 is a specific and potent histone deacetylase 8 (HDAC8) inhibitor, with >200-fold selectivity over the other HDAC isoforms.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
HDAC8 IC50 10nM
HDAC6 IC50 2.9μM
HDAC1 IC50 4μM
HDAC10 IC50 13μM
HDAC2 IC50 >50μM
HDAC3 IC50 >50μM

6 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
A549 GI50 > 20000 nM Antiproliferative activity against human A549 cells after 72 hrs by MTS assay [PMID: 30004697]
A549 IC50 2000 nM Antiproliferative activity against human A549 cells after 72 hrs by CellTiter Glo assay [PMID: 35797900]
BE(2)-C IC50 19.9 μM Cytotoxicity against human BE(2)-C cells assessed as reduction in cell viability by measuring metabolic activity after 72 hrs by WST-8 assay [PMID: 29190092]
BXPC-3 GI50 > 20000 nM Antiproliferative activity against human BxPC3 cells after 72 hrs by MTS assay [PMID: 30004697]
CCRF-HSB-2 GI50 2.4 μM Antiproliferative activity against human HSB2 cells by alamar blue assay [PMID: 29505935]
HCT-116 GI50 2600 nM Antiproliferative activity against human HCT-116 cells after 72 hrs by CellTiter Glo assay [PMID: 35797900]
HCT-116 GI50 2640 nM Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay [PMID: 30004697]
HEL IC50 10.8 μM Antiproliferative activity against human HEL cells after 48 hrs by MTT assay [PMID: 29533873]
HeLa IC50 > 100 μM Inhibition of HDAC in human HeLa cells nuclear extracts by fluorometric assay [PMID: 23116147]
HeLa IC50 > 25 μM Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay [PMID: 29533873]
HH GI50 > 100 μM Growth inhibition of human HH cells incubated for 72 hrs by MTS assay [PMID: 23116147]
HT-29 IC50 > 10000 nM Antiproliferative activity against human HT-29 cells after 72 hrs by CellTiter Glo assay [PMID: 35797900]
HT-29 GI50 > 10000 nM Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay [PMID: 30004697]
Huh-7 EC50 1.8 μM Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by luciferase reporter gene assay [PMID: 25490700]
Huh-7 CC50 11 μM Cytotoxicity against human HuH7 cells assessed as inhibition of cell viability after 3 days by CellTiter 96 assay [PMID: 25490700]
HuT78 GI50 2.4 μM Antiproliferative activity against human HUT78 cells by alamar blue assay [PMID: 29505935]
Jurkat GI50 11 μM Growth inhibition of human Jurkat cells incubated for 72 hrs by MTS assay [PMID: 23116147]
Jurkat GI50 2.4 μM Antiproliferative activity against human Jurkat cells by alamar blue assay [PMID: 29505935]
Jurkat IC50 4.5 μM Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay [PMID: 29533873]
K562 IC50 > 25 μM Antiproliferative activity against human K562 cells after 48 hrs by MTT assay [PMID: 29533873]

20 records · Scroll to view more

PCI-34051 Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of PCI-34051 from 3 published references. In vitro models include hHDAC8. In vivo models include 3-week-old C57BL/6J mice.

PCI-34051 In Vitro Studies

In the hHDAC8 model, reaction with the compound yielded HDX-decreasing peptides compared with the unbound state. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Decreased Deuterium Uptake in hHDAC8

Cell-based study · hHDAC8 [1]

In the hHDAC8 model, reaction with the compound yielded HDX-decreasing peptides compared with the unbound state.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
deuterium uptakeReported result 12 HDX-decreasing peptides were observed.[1]

Literature-Reported Treatment Conditions

Exposure duration
37 °C for 30 min
Method
reacted at a molar ratio
Reported limits
Not stated in the sentences used: vehicle. Removed after verification: value. Concentration removed by unit check.
Methods and source locations

Compound reported in the paper: PCI-34051

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Native MS of hHDAC8-inhibitor complexes (S3, S4); Results > HDX-MS differences upon inhibitor binding (S51, S67, S68); Methods > Hydrogen-deuterium exchange mass spectrometry (S157, S158, S159)

deuterium uptake: deuterium uptake; comparator: unbound state — Results > HDX-MS differences upon inhibitor binding (S51, S67, S68)

PCI-34051 In Vivo Studies

In female BALB/C mice with asthma, the PCI-34051 and givinostat groups had significantly lower Penh values than the asthma group. The asthma group also had significantly higher total BALF cell numbers than the DXM, TSA, PCI-34051, and givinostat groups. In male mice, daily intraperitoneal PCI-34051 treatment reduced BAPN-induced AD incidence compared with BAPN + DMSO, with reported incidences of 70.59% versus 40%. [2,3]

Enhanced Pause in a Mouse Asthma Model

Animal study · mouse model of asthma; female BALB/C mice; n = 8 for each group [2]

Female BALB/C mice in an asthma model received PCI-34051 at 0.5 mg/kg by intraperitoneal injection 30 min before excitation. The PCI-34051 and givinostat groups had significantly lower enhanced pause (Penh) values than the asthma group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Enhanced pause (Penh)Reported result All four treatment groups, including DXM, TSA, PCI-34051, and givinostat groups, had significantly lower Penh values compared with the asthma group.[2]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
30 min before excitation
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
PCI-34051 0.5 mg/kgasthma groupAll four treatment groups, including DXM, TSA, PCI-34051, and givinostat groups, had significantly lower Penh values compared with the asthma group.[2]
PCI-34051 0.5 mg/kg
Model: mouse model of asthma; female BALB/C mice; n = 8 for each group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: PCI-34051

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Mice and treatment (S1, S2, S8, S9, S10); Materials and methods > Detection of airway responsiveness (S14); Results (S52, S55)

Enhanced pause (Penh): Enhanced pause (Penh); comparator: asthma group — Materials and methods > Detection of airway responsiveness (S14); Results (S52)

PCI-34051 0.5 mg/kg · Materials and methods > Mice and treatment (S10); Results (S52)

BAPN-induced aortic dissection incidence in mice

Animal study · 3-week-old C57BL/6J mice [3]

PCI-34051 was injected intraperitoneally at a dose of 30 mg/kg every day. After four weeks of treatment, compared to DMSO, treatment with PCI-34051 resulted in a reduction in the incidence (70.59% vs. 40%) of BAPN-induced AD in male mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The incidence of AD or aortic dilationAD incidence male mice, after four weeks of treatment: 70.59% vs. 40%[3]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
every day
Vehicle
DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
PCI-34051 30 mg/kgBAPN + DMSOAfter four weeks of treatment, compared to DMSO, treatment with PCI-34051 resulted in a reduction in the incidence (70.59% vs. 40%) of BAPN-induced AD in male mice.[3]
PCI-34051 30 mg/kg
Model: 3-week-old C57BL/6J mice
Methods and source locations

Compound reported in the paper: PCI-34051

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > PCI-34051 attenuated BAPN-induced AD through inhibiting ferroptosis in mice (S58, S59); Methods > Animal experiments (S76); Figure 7. legend (S252)

The incidence of AD or aortic dilation: The incidence of AD or aortic dilation; comparator: BAPN + DMSO — Results > PCI-34051 attenuated BAPN-induced AD through inhibiting ferroptosis in mice (S59); Figure 7. legend (S252)

PCI-34051 30 mg/kg · Results > PCI-34051 attenuated BAPN-induced AD through inhibiting ferroptosis in mice (S58, S59)

BALF Total Cell Numbers in a Mouse Asthma Model

Animal study · mouse model of asthma; female BALB/C mice; n = 6 for each group [2]

Female BALB/C mice in an asthma model received PCI-34051 at 0.5 mg/kg by intraperitoneal injection 30 min before excitation. The asthma group had significantly higher total cell numbers in BALF than the DXM, TSA, PCI-34051, and givinostat groups.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
total cells and cells of different types in BALFReported result The asthma group had significantly higher total cell numbers than the DXM, TSA, PCI-34051, and givinostat groups (all p < 0.001).[2]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
30 min before excitation
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
PCI-34051 0.5 mg/kgasthma groupThe asthma group had significantly higher total cell numbers than the DXM, TSA, PCI-34051, and givinostat groups (all p < 0.001).[2]
PCI-34051 0.5 mg/kg
Model: mouse model of asthma; female BALB/C mice; n = 6 for each group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: PCI-34051

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Mice and treatment (S1, S2, S8, S9, S10); Materials and methods > Quantification of various types of cells in BALF (S25); Results (S74, S76)

total cells and cells of different types in BALF: total cells and cells of different types in BALF; comparator: asthma group — Materials and methods > Quantification of various types of cells in BALF (S25); Results (S74)

PCI-34051 0.5 mg/kg · Materials and methods > Mice and treatment (S10); Results (S74)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 950762-95-5
Applications HDAC inhibitor
Formula C17H16N2O3
Molecular Weight 296.3
SMILES
COC1=CC=C(C=C1)CN2C=CC3=C2C=C(C=C3)C(=O)NO

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 58 mg/mL (195.73 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
5% DMSO+40%PEG300+5% tween80+50% H2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

PCI-34051 Research References

  1. [1] Luo Y, Yan Z, Chu X, et al. Binding mechanism and distant regulation of histone deacetylase 8 by PCI-34051. Commun Biol (2025). PMID: 39939814 DOI: 10.1038/s42003-025-07649-0 Source material
  2. [2] Ren Y, Su X, Kong L, et al. Therapeutic effects of histone deacetylase inhibitors in a murine asthma model. Inflamm Res (2016). PMID: 27565183 DOI: 10.1007/s00011-016-0984-4 Source material
  3. [3] Ye J, Shi J, Yi X, et al. HDAC8-selective inhibitor PCI-34051 protects against aortic dissection by attenuating ferroptosis of vascular smooth muscle cells. Life Med (2026). PMID: 42281825 DOI: 10.1093/lifemedi/lnag013 Source material

Added to your cart

View Cart Checkout
Loading...